Caster Semenya stars at Meeting de Montreuil ahead of appeal outcome

A day after being selected in South Africa's World Championships preliminary squad, Caster Semenya claimed victory in a 2000 metres race.

Published : Jun 12, 2019 11:47 IST

Caster Semenya has insisted she will not take hormone-suppressing medication in order to comply with the regulation if her appeal is unsuccessful.
Caster Semenya has insisted she will not take hormone-suppressing medication in order to comply with the regulation if her appeal is unsuccessful.
lightbox-info

Caster Semenya has insisted she will not take hormone-suppressing medication in order to comply with the regulation if her appeal is unsuccessful.

Caster Semenya had no problems stepping up to compete at 2000 metres on Tuesday, dominating the field to triumph at the Meeting de Montreuil.

In action a day after being selected in South Africa's preliminary squad for the IAAF World Championships, Semenya clocked a time of five minutes and 38.19 seconds at the event. The two-time Olympic 800m champion was named in a 40-strong party while awaiting the outcome of an appeal to the Federal Supreme Court of Switzerland in a bid to overturn a new IAAF ruling.

The Court of Arbitration for Sport (CAS) ruled that the IAAF could implement a regulation to impose restrictions on testosterone levels in athletes competing in women's events at distances ranging from 400m to one mile.

Semenya has insisted she will not take hormone-suppressing medication in order to comply with the regulation if her appeal is unsuccessful, arguing the rule contravenes her human rights.

The Swiss Supreme Court has stated Semenya can compete without restrictions while it considers the case, though the IAAF is seeking a "swift reversion" to that order.

Semenya ruled out retiring after winning the 800m at the Diamond League event in Doha in May.

Sign in to unlock all user benefits
  • Get notified on top games and events
  • Save stories to read later
  • Access to comment on every story
  • Sign up / manage to our newsletters with a single click
  • Get notified by email for early bird access to discounts & offers to our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide to our community guidelines for posting your comment